报价延迟最少15分钟:2025/01/21 08:41 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
156.39 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.93/0.10
|
|
企业价值
9.01B
|
| 资产负债 |
|
每股账面净值
12.12
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
314.71M
|
|
每股收益
5.51
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/01/21 08:41 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |